Membranolytic anticancer peptides (ACPs) are drawing increasing attention as potential future therapeutics against cancer, due to their ability to hinder the development of cellular resistance and their potential to overcome common hurdles of chemotherapy, e.g., side effects and cytotoxicity. In this work, we present an ensemble machine learning model to design potent ACPs. Four counter-propagation artificial neural-networks were trained to identify peptides that kill breast and/or lung cancer cells. For prospective application of the ensemble model, we selected 14 peptides from a total of 1000 de novo designs, for synthesis and testing in vitro on breast cancer (MCF7) and lung cancer (A549) cell lines. Six de novo designs showed anticancer activity in vitro, five of which against both MCF7 and A549 cell lines. The novel active peptides populate uncharted regions of ACP sequence space.
Bibliographical noteFunding Information:
Acknowledgments The authors thank Sarah Haller for technical support. This research was financially supported by the Swiss National Science Foundation (grants no. CRSII2_160699, no. 200021_157190 and no. IZSEZ0_177477). M.H. was financially supported by BTobitate! (Leap for tomorrow)^ study abroad initiative (Japan’s Ministry of Education, Culture, Sports, Science, and Technology [MEXT]).
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
- Artificial intelligence
- Machine learning
- Peptide design
- A549 Cells
- Neural Networks, Computer
- Models, Molecular
- Neoplasms/drug therapy
- Antineoplastic Agents/chemistry
- Machine Learning
- MCF-7 Cells
- Cell Proliferation/drug effects